INTRODUCTION: Renal cell carcinoma (RCC) is still a challenging disease.
Over the last 6 years, the use of novel targeted therapies interfering with vascularization and inhibition of other downstream pathways has revolutionized the therapy of this disease, leading to an improvement of patient outcomes. In particular, dysregulation of the vascular endothelial growth factor (VEGF) pathway and VEGF protein overexpression have proved important, as they result in increased tumor angiogenesis and RCC growth and development.
AREAS COVERED: This review briefly discusses the mechanisms of action and clinical applications of pazopanib . It mainly outlines the safety and tolerability of pazopanib for locally advanced/metastatic RCC. Phase III pazopanib safety data are also indirectly compared with other standard, antiangiogenic receptor tyrosine kinase inhibitors currently used in the management of RCC.
EXPERT OPINION: Pazopanib is a new drug available in the oncology portfolio to treat patients with predominantly clear-cell RCC. The toxicity profile of pazopanib is comparable, but in some ways distinct, from other antiangiogenic drugs used in the treatment of RCC. Long-term data about late side effects of this treatment are awaited.
Written by:
Zivi A, Cerbone L, Recine F, Sternberg CN. Are you the author?
San Camillo-Forlanini Hospital, Department of Medical Oncology, Circonvallazione Gianicolense 87, 00152, Rome, Italy.
Reference: Expert Opin Drug Saf. 2012 Sep;11(5):851-9.
doi: 10.1517/14740338.2012.712108
PubMed Abstract
PMID: 22861374
UroToday.com Renal Cancer Section
